{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T05:01:29.964037+00:00","company":{"ticker":"LFVN","cik":849146,"company_name":"Lifevantage Corp"},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"b7641fd0fd0a20b9efd11ad26fd0bf23e64085f8","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$0.11 per diluted share","guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":"$1.4 million","period_text":"the three months ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$43.7 million"},"claim":"Lifevantage Corp reported the three months ended March 31, 2026 results: revenue $43.7 million, net income $1.4 million, EPS $0.11 per diluted share. Guidance lowered.","evidence_excerpt":"For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 System Ò , partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%. Gross profit for the third quarter of fiscal 2026 was $34.5 million, or 79.0% of revenue, compared to $47.3 million, or 81.0% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System Ò , along with increases in shipping and warehouse related expenses. Adjusted for the allo","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-208934","anchor_url":"https://secwatch.observer/filing/0001193125-26-208934#claim-b7641fd0fd0a20b9efd11ad26fd0bf23e64085f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000119312526208934/0001193125-26-208934-index.htm"},{"fact_type":"executive_change","fact_key":"a4c0eb0f3b","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-08-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rajendran Anbalagan was appointed as Director at Lifevantage Corp.","evidence_excerpt":"On August 26, 2024, the Board, based on the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Rajendran Anbalagan as a member of the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000849146-24-000064","anchor_url":"https://secwatch.observer/filing/0000849146-24-000064#claim-a4c0eb0f3b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000064/0000849146-24-000064-index.htm"},{"fact_type":"executive_change","fact_key":"3bf64183f4","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-08-26T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-08-26","interim":false,"role":"Director","role_category":"director","successor_name":"Rajendran Anbalagan","successor_named":true},"claim":"Erin Brockovich resigned as Director at Lifevantage Corp.","evidence_excerpt":"On August 23, 2024, Erin Brockovich, a member of the Board of Directors (the “Board”) of LifeVantage Corporation (the “Company”), notified the Company of her resignation as a member of the Board and any committees of the Board, effective August 26, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000849146-24-000064","anchor_url":"https://secwatch.observer/filing/0000849146-24-000064#claim-3bf64183f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000064/0000849146-24-000064-index.htm"},{"fact_type":"earnings_release","fact_key":"5a41ea2782eb57d79d7e8fb2e5ba6289cc6d233d","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.13 per diluted share","guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":"$1.7 million","period_text":"three and nine months ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$48.2 million"},"claim":"Lifevantage Corp reported three and nine months ended March 31, 2024 results: revenue $48.2 million, net income $1.7 million, EPS $0.13 per diluted share. Guidance lowered.","evidence_excerpt":"health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2024. Third Quarter Fiscal 2024 Summary*: • Revenue of $48.2 million, a decrease of 10.2% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue was down approximately 8.7%; • Revenue in","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000849146-24-000048","anchor_url":"https://secwatch.observer/filing/0000849146-24-000048#claim-5a41ea2782eb57d79d7e8fb2e5ba6289cc6d233d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000048/0000849146-24-000048-index.htm"},{"fact_type":"debt_financing","fact_key":"ba8b4dff0ff914472f321f18da7d30d303fd7ce6","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-04-16T23:59:59+00:00","payload":{"counterparty":"Bank of America, N.A.","effective_date":"2024-04-12","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"the greater of the Term SOFR Daily Floating Rate or 0.00%, plus 2.00%","item_codes_triggered":["2.03"],"maturity_text":"April 12, 2027","principal_text":"$5,000,000"},"claim":"Lifevantage Corp incurred revolving credit of $5,000,000 with Bank of America, N.A. at the greater of the Term SOFR Daily Floating Rate or 0.00%, plus 2.00% maturing April 12, 2027.","evidence_excerpt":"The Loan Agreement provides for a revolving line of credit in aggregate principal amount not to exceed $5,000,000 (the \"Line of Credit\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000849146-24-000039","anchor_url":"https://secwatch.observer/filing/0000849146-24-000039#claim-ba8b4dff0ff914472f321f18da7d30d303fd7ce6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/0000849146-24-000039-index.htm"},{"fact_type":"material_agreement","fact_key":"584cda9a3a9b24f51c0dbda391fdf3494be804c3","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Loan Agreement","agreement_type":"credit_facility","counterparty":"Bank of America, N.A.","effective_date":"2024-04-12","item_codes_triggered":["1.01"],"value_text":"$5,000,000"},"claim":"Lifevantage Corp entered into Loan Agreement with Bank of America, N.A. valued at $5,000,000 (effective 2024-04-12).","evidence_excerpt":"On April 12, 2024, LifeVantage Corporation (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Bank of America, N.A., as Lender (the “Lender”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000849146-24-000039","anchor_url":"https://secwatch.observer/filing/0000849146-24-000039#claim-584cda9a3a9b24f51c0dbda391fdf3494be804c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000039/0000849146-24-000039-index.htm"},{"fact_type":"material_agreement","fact_key":"8beb581fbf466a9de91c0bd5a64a03422cbf3e85","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Cooperation Agreement","agreement_type":"other","counterparty":"the entities and persons listed on Exhibit A and Exhibit B (collectively, the Stockholder Parties)","effective_date":"2024-02-14","item_codes_triggered":["1.01"],"value_text":null},"claim":"Lifevantage Corp entered into Cooperation Agreement with the entities and persons listed on Exhibit A and Exhibit B (collectively, the Stockholder Parties) (effective 2024-02-14).","evidence_excerpt":"LifeVantage Corporation (the “Company”) entered into a Cooperation Agreement (the “Agreement”) with the entities and persons listed on Exhibit A thereto (collectively, the “Radoff Parties”) and the entities and persons listed on Exhibit B thereto (collectively, the “Sudbury Parties,” and together with the Radoff Parties, the “Stockholder Parties”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000849146-24-000021","anchor_url":"https://secwatch.observer/filing/0000849146-24-000021#claim-8beb581fbf466a9de91c0bd5a64a03422cbf3e85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/0000849146-24-000021-index.htm"},{"fact_type":"executive_change","fact_key":"11133b65ab","cik":849146,"ticker":"LFVN","company_name":"Lifevantage Corp","filed_at":"2024-02-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dayton Judd was appointed as Director at Lifevantage Corp.","evidence_excerpt":"Effective as of February 14, 2024, Mr. Judd has been appointed as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000849146-24-000021","anchor_url":"https://secwatch.observer/filing/0000849146-24-000021#claim-11133b65ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914624000021/0000849146-24-000021-index.htm"}]}